NEWS: Phase III Development of Non Small Cell Lung Cancer Treatment Extended to Japan
London, UK, and Cambridge, MA (March 25, 2009) - Antisoma plc announces that ATTRACT-1, the Novartis phase III trial evaluating ASA404 as a first-line treatment for non-small cell lung cancer, is now enrolling patients in Japan. ATTRACT-1 has been enrolling patients in a variety of other countries since it began in April 2008. Extension of the trial to Japan follows the successful completion of a phase I study evaluating the safety of ASA404 in Japanese lung cancer patients.
еннто точно…
Инженер конструктор ATTRACT-1 has been enrolling patients in a variety of other countries since it began in April 2008. Extension of […….
Прикольно, я тронут)…
Дизайнер, художник ATTRACT-1 has been enrolling patients in a variety of other countries since it began in April 2008. Extension of […….
Я думаю, что Вы не правы….
Менеджер по рекламе ATTRACT-1 has been enrolling patients in a variety of other countries since it began in April 2008. Extension of […….